PFE
Pfizer Inc. (PFE) Stock Analysis
Research Pfizer Inc. (PFE) with company financials, earnings context, valuation indicators, risk analysis and related market news.
Research record updated: . Individual measures may refer to different reporting periods.
- Ticker
- PFE
- Company
- Pfizer Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market cap
- $156.73B
- Financial data source
- Yahoo Finance + SEC company filings + FMP cash flow statements + FMP balance sheet + income statements + StockAnalysis complete statements
- Annual revenue (reporting year not supplied)
- $62.58B
- Annual net income (reporting year not supplied)
- $7.77B
- Annual free cash flow (reporting year not supplied)
- $9.08B
- Trailing revenue
- $63.70B
- Trailing net income
- $4.33B
- Total assets
- $208.16B
- Total liabilities
- $121.39B
Pfizer Inc. (PFE) Stock Analysis research
Review the available company profile, financial history, valuation context and investor signals for Pfizer Inc.. Compare the reported operating results with the valuation and risk measures below.
The figures are cached research data and can change after new filings, earnings reports or market updates. Verify material facts with primary company disclosures before making an investment decision.
Latest related news
Vaxcyte’s VAX-31 Phase 3 Win Raises the Competitive Bar
VAX-31 met all prespecified OPUS-1 endpoints in adults, supporting broader pneumococcal coverage while regulatory and manufacturing risks remain.
Novavax’s Plague-Scare Rally Was Disconnected From Its Pipeline
Novavax has no plague vaccine, so its headline-driven rally did not change the company’s partner royalties, milestones or commercial outlook.
Vaxcyte Phase 3 Data Strengthen VAX-31, but Two Trials Still Matter
VAX-31 met OPUS-1 primary endpoints across shared and unique serotypes. OPUS-2, OPUS-3, manufacturing and filing execution remain key risks.
VAX-31 Creates a Longer-Term Competitive Risk for Pfizer Prevnar
VAX-31 Phase 3 results create a credible future threat to Pfizer Prevnar, but follow-up trials, filing timing, manufacturing and adoption remain open.